Tranche Update on Getein Biotech, Inc's Equity Buyback Plan announced on December 31, 2020.
April 01, 2021
Share
From December 30, 2020 to March 31, 2021, the company has repurchased 1,169,275 shares, representing 0.32% for CNY 36.82 million. With this, the company has completed the repurchase of 1,169,275 shares, representing 0.32% for CNY 36.82 million under the buyback announced on December 31, 2020.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 